ORAI3 and breast carcinoma: Likewise, Orai3 overexpression in T47D breast cancer cells confers resistance to pro-apoptotic agents (thapsigargin and staurosporine) and chemotherapeutics (cisplatin, 5-FU, and paclitaxel) [146].